We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Dulaglutideis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Dulaglutide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2014–2021 with a typical study size of 1,201 participants.
Based on 12 studies · 2 meta-analyses · 10 RCTs · 35,091 total participants
Confidence
HighBy outcome
Dulaglutide has an evidence score of 7/10 — strong evidence based on 12 indexed studies, including 2 meta-analyses. An FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is included here for reference only, not as a supplement and not auto-recommended. Representative study: PMID 31422062.
The commonly studied dose of Dulaglutide is Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 12 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Dulaglutide (GLP-1 receptor agonist)
An FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is included here for reference only, not as a supplement and not auto-recommended.
Strong, consistent large-RCT evidence from the AWARD program plus the 9,901-patient REWIND cardiovascular-outcomes trial and confirmatory meta-analyses; capped below top tier because it is a prescription drug with notable risks, not a supplement.
Dulaglutide is a long-acting analogue of the gut incretin hormone GLP-1 (glucagon-like peptide-1), formatted as a fusion of two GLP-1 analogue molecules to an Fc fragment so it can be dosed once weekly by subcutaneous injection.
It is a prescription drug, NOT a dietary supplement: branded as Trulicity and approved by the FDA for type 2 diabetes, with an additional indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Mechanistically it activates the GLP-1 receptor in the pancreas (glucose-dependent insulin secretion, suppressed glucagon), brain (appetite suppression and satiety), and gut (slowed gastric emptying). The evidence base is genuinely strong.
The AWARD program — a series of phase-3 RCTs — established efficacy across the diabetes treatment ladder: dulaglutide beat placebo and exenatide (AWARD-1), was non-inferior to once-daily liraglutide on HbA1c (AWARD-6), was superior to insulin glargine on HbA1c with weight loss instead of weight gain (AWARD-2), worked as add-on to SGLT2 inhibitors (AWARD-10), and showed dose-related additional HbA1c lowering at the higher 3.0/4.5 mg doses (AWARD-11).
The landmark REWIND cardiovascular-outcomes trial randomized 9,901 patients with type 2 diabetes — most WITHOUT prior cardiovascular disease — and found a 12% relative reduction in the composite of cardiovascular death, non-fatal MI, or non-fatal stroke (HR 0.88, 95% CI 0.79-0.99) over a median 5.4 years, with exploratory benefits on renal outcomes.
A pooled meta-analysis of all seven GLP-1 cardiovascular-outcomes trials (including REWIND) confirmed a class-level 12% MACE reduction (HR 0.88) and a 17% reduction in a composite kidney outcome, with no increase in pancreatitis or pancreatic cancer.
The honest counterweight: dulaglutide carries a boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma) and is contraindicated with a personal/family history of medullary thyroid carcinoma or MEN2; it carries risks of pancreatitis and gallbladder disease; gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common; its weight loss is real but modest (typically a few kilograms, less than semaglutide — head-to-head SUSTAIN 7 showed semaglutide lowered HbA1c and weight more); and FDA-equivalent warnings about compounded/grey-market GLP-1 products apply.
It should be used only under a clinician's care, for a genuine medical indication.
A long-acting GLP-1 analogue (fused to an Fc fragment for once-weekly dosing) that binds and activates the GLP-1 receptor in the pancreas, brain, and gastrointestinal tract — the single upstream target driving all downstream effects.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering fasting and postprandial glucose and HbA1c with low intrinsic hypoglycemia risk.
Acts on central appetite-regulating circuits to increase satiety and reduce food intake — the driver of the modest weight loss (typically a few kilograms) seen across the AWARD trials.
Delays gastric emptying, blunting post-meal glucose excursions and prolonging fullness — and the mechanism behind much of the nausea seen during initiation.
How Dulaglutide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.
Loading: Typically started at 0.75 mg once weekly and stepped up (1.5 → 3.0 → 4.5 mg) at intervals of at least 4 weeks to limit GI side effects — done under clinician supervision.
Can be taken without food
| Form | Type |
|---|---|
| 💊Subcutaneous once-weekly pen (Trulicity) | Recommended |
Only the once-weekly subcutaneous pen is approved. Avoid compounded/grey-market GLP-1 products — regulators have warned about dosing errors and impurities in non-pharmacy products.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Once weekly, the same day each week, any time of day, with or without food. Dosing is titrated upward by a clinician — never self-escalate.
Dose-response data unavailable. The current published research for Dulaglutide does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Large, consistent HbA1c reductions across the AWARD phase-3 program; non-inferior to liraglutide (AWARD-6) and superior to insulin glargine (AWARD-2) and exenatide (AWARD-1).
12% relative reduction in major adverse cardiovascular events in the dedicated REWIND outcomes trial (HR 0.88) — notable because most participants had no prior cardiovascular disease.
Real but modest weight reduction (typically a few kilograms, dose-dependent) — less than semaglutide head-to-head (SUSTAIN 7). Weight goes down rather than up versus insulin.
Nausea, vomiting and diarrhea are the most frequent adverse events — usually mild-to-moderate and most pronounced during dose escalation, but a common reason for discontinuation.
Exploratory REWIND analysis and the pooled GLP-1 meta-analysis show reduced macroalbuminuria and a composite kidney benefit — mainly driven by lower urinary albumin excretion.
Contraindicated — boxed warning for thyroid C-cell tumors.
Use with caution under specialist guidance; generally avoid with prior pancreatitis.
Contraindicated — discontinue before a planned pregnancy under clinician guidance.
Not appropriate — this is a prescription diabetes drug with real risks, not a cosmetic shortcut. Use only for a clinician-confirmed indication.
Combining with insulin or sulfonylureas raises hypoglycemia risk; the clinician typically reduces those agents. Dulaglutide alone is low-hypoglycemia (glucose-dependent action).
Delayed gastric emptying can change the absorption of co-administered oral drugs; clinician monitoring advised, especially for narrow-therapeutic-index medicines.
Tip: Gradual dose titration; smaller meals; usually transient as the body adapts
Tip: Slow titration, hydration, dietary adjustment; report severe/persistent symptoms to a clinician
Tip: Seek care for upper-right abdominal pain, fever, or jaundice
Tip: Discontinue and seek urgent care for severe, persistent abdominal pain radiating to the back
Tip: Asymptomatic enzyme elevations are recognized; clinician monitors and evaluates symptomatic cases
Timing is flexible for Dulaglutide — consistent daily use matters more than the time of day. Once-weekly subcutaneous injection on the same day each week, with or without food, at any time of day.
Dulaglutide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea, vomiting / diarrhea, gallbladder disease (cholelithiasis / cholecystitis). Use caution if any of these apply to you: Personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN2); Prior serious hypersensitivity to dulaglutide or any GLP-1 receptor agonist.
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Do not combine with another GLP-1 agonist (e.g. semaglutide, liraglutide, exenatide) or a GIP/GLP-1 agonist (tirzepatide) — additive risk with no added benefit.
Tip: Dose reduction of background insulin/sulfonylurea by the prescribing clinician